Page last updated: 2024-10-28

guanfacine and Epilepsy, Temporal Lobe

guanfacine has been researched along with Epilepsy, Temporal Lobe in 1 studies

Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Epilepsy, Temporal Lobe: A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the TEMPORAL LOBE, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic. (From Adams et al., Principles of Neurology, 6th ed, p321).

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Swartz, BE	1
Kovalik, E	1
Thomas, K	1
Torgersen, D	1
Mandelkern, MA	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885]				16 participants (Actual)	Interventional	2008-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Inferior Parietal Lobule

"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Intervention	percent change in saline signal (Mean)
Guanfacine	-0.17
Placebo	-0.094

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Middle Frontal Gyrus

Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Intervention	percent change in saline signal (Mean)
Guanfacine	-0.1
Placebo	0.052

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Superior Frontal Gyrus

Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Intervention	percent change in saline signal (Mean)
Guanfacine	-0.134
Placebo	-0.086

Trials

1 trial available for guanfacine and Epilepsy, Temporal Lobe

Article	Year
The effects of an alpha-2 adrenergic agonist, guanfacine, on rCBF in human cortex in normal controls and subjects with focal epilepsy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2000, Volume: 23, Issue:3 Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Blood Pressure; Cerebral Cor	2000